Aim:This study aimed to investigate the effectiveness and safety of whole-body hyperthermia (WBH) in cancer patients, identifying predictive factors for successful treatment (reaching target temperature ≥ 38.5 °C) and assessing adverse effects.Methods:We conducted a retrospective analysis of 397 cancer patients receiving a total of 855 WBH treatment sessions at a single institution between January 2018 and December 2018.Results:A total of 855 WBH treatments were performed on 397 patients (76.6% female; median age 58 years). The most common cancer types included breast cancer (52.4%), followed by prostate cancer (13.1%) and gynecological cancers (10.6%), with 54.7% of patients having metastatic disease. Target temperature was reached in 90.1% (770 of 855) of sessions, with a median treatment time of 202 min and maximum temperature of 40.4 °C. Common side effects included headache (54.9%), skin reactions (11.7%), and cardiac effects (9.4%), with no serious adverse events. Serum creatinine (p= 0.01, OR 0.30, 95% CI: 0.11–0.78) and secale cornutum/galena co-medication during WBH (p< 0.001, OR 0.26 [0.12, 0.54]) emerged as independent predictors of achieving target temperature in multivariate analysis. Both elevated creatinine levels and the use of secale cornutum/galena were associated with an approximately 70% lower probability of achieving the target temperature.Conclusions:WBH demonstrates safety in cancer patients with high success rates in reaching target temperatures. Both elevated creatinine levels and the use of secale cornutum/galena were associated with a lower chance of reaching the target temperature and thus impacting and predicting WBH success.
目的：本研究旨在探讨全身热疗（WBH）在癌症患者中的有效性与安全性，识别治疗成功（达到目标温度≥38.5°C）的预测因素，并评估其不良反应。 方法：我们对2018年1月至2018年12月期间在同一机构接受全身热疗的397例癌症患者进行了回顾性分析，共纳入855次治疗记录。 结果：397例患者（女性占76.6%；中位年龄58岁）共接受855次全身热疗。最常见的癌症类型包括乳腺癌（52.4%），其次为前列腺癌（13.1%）和妇科肿瘤（10.6%），其中54.7%的患者存在转移性疾病。90.1%（855次中的770次）的治疗达到目标温度，中位治疗时间为202分钟，最高温度为40.4°C。常见副作用包括头痛（54.9%）、皮肤反应（11.7%）和心脏影响（9.4%），未发生严重不良事件。多变量分析显示，血清肌酐水平（p=0.01，OR 0.30，95% CI：0.11–0.78）及全身热疗期间使用麦角/方铅矿联合用药（p<0.001，OR 0.26 [0.12, 0.54]）是达到目标温度的独立预测因素。肌酐水平升高和麦角/方铅矿的使用均与达到目标温度的概率降低约70%相关。 结论：全身热疗在癌症患者中安全性良好，达到目标温度的成功率高。肌酐水平升高和麦角/方铅矿的使用均会降低达到目标温度的可能性，从而影响并预测全身热疗的成功率。
肿瘤(癌症)患者之家